Abstract
INTRODUCTION White matter (WM) energy supply is crucial for axonal function and myelin maintenance. Providing ketones, the brain’s alternative fuel to glucose, is a therapeutic strategy to bypass the brain’s glucose-specific energy deficit in mild cognitive impairment (MCI). How an additional supply of ketones affects glucose or ketone uptake in specific WM fascicles in MCI has not previously been described.
METHODS This 6-month interventional study included MCI participants randomized to a placebo (n = 16) or ketogenic medium chain triglyceride (kMCT; n = 17) drink. A neurocognitive battery and brain imaging were performed pre- and post-intervention. WM fascicle uptake of ketone and glucose and structural properties were assessed using positron emission tomography and diffusion imaging, respectively.
RESULTS Ketone uptake was increased by 2.5 to 3.2-fold in nine fascicles of interest (P < 0.001) only in the kMCT group, an effect seen both in deep WM and in fascicle cortical endpoints. Improvement in processing speed was associated with WM ketone uptake globally and in individual fascicles, most importantly the fornix (r = +0.61; P = 0.014).
DISCUSSION A 6-month ketogenic supplementation in MCI improved WM energy supply globally. The significant positive association with processing speed suggests that ketones may have a role in myelin integrity in MCI.
Competing Interest Statement
SCC has consulted for or received travel honoraria or test products from Nestle Health Science, Bulletproof, Cerecin, and Abitec. SCC is the founder and director of the consulting company, Senotec Ltd. MD is CSO and shareholder of Imeka Solutions Inc (www.imeka.ca) and MR is consultant for Imeka Solutions Inc.
Clinical Trial
NCT02551419
Funding Statement
Financial support for the BENEFIC trial was provided by the Alzheimer Association USA (PCTR-15-328047), FRQS (FR40072), and University of Sherbrooke. MR was funded by MITACS and Nestle Health Science. The University of Sherbrooke Institutional Chair in Neuroinformatics also provided funding support. Abitec provided the kMCT (Captex 355) and placebo oil. The intervention drinks for both arms were prepared under contract at INAF, University Laval, Quebec, QC, Canada.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional ethical committee (CIUSSS de l Estrie CHUS Sherbrooke Quebec Canada).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵1 co-senior authors
Conflicts of interest SCC has consulted for or received travel honoraria or test products from Nestlé Health Science, Bulletproof, Cerecin, and Abitec. SCC is the founder and director of the consulting company, Senotec Ltd. MD is CSO and shareholder of Imeka Solutions Inc (www.imeka.ca) and MR is consultant for Imeka Solutions Inc.
Data Availability
Original data and processed data will be made available upon request. All processing steps and results can be reproduced using the TractoFlow pipeline.
Abbreviations
- AD
- Alzheimer’s disease
- MCI
- mild cognitive impairment
- WM
- white matter
- kMCT
- ketogenic medium chain triglyceride
- ApoE4
- apolipoprotein E4
- MMSE
- Mini-Mental State Examination
- MoCA
- Montreal Cognitive Assessment score
- MRI
- magnetic resonance imaging
- DTI
- diffusion tensor imaging
- CSF
- cerebrospinal fluid
- WMH
- white matter hyperintensities
- PET
- positron emission tomography
- FDG
- 18F-flurodeoxyglucose
- AcAc
- 11C-acetoacetate
- β-HB
- beta-hydroxybutyrate
- PCC
- posterior cingulate segment of the cingulum
- PHC
- parahippocampal segment of the cingulum
- FX
- fornix
- AF
- arcuate fasciculus
- CC2
- genu of the corpus callosum
- CC7
- splenium of the corpus callosum
- IFOF
- inferior fronto-occipital fasciculus
- ILF
- inferior longitudinal fasciculus
- UF
- uncinate fasciculus
